FDA Review Of Follow-On Biologics Would Put Brands, Generics Under One Roof
Executive Summary
The pending legislation to create a pathway for approval of follow-on biologics would also create a new organizational template for review of generic products
You may also be interested in...
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs
FDA's Office of Generic Drugs is poised to enter a new era with new leadership, even as the agency is saying it will draw on the expertise of veteran officials for key initiatives
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs
FDA's Office of Generic Drugs is poised to enter a new era with new leadership, even as the agency is saying it will draw on the expertise of veteran officials for key initiatives
Biosimilar “Interchangeability” Standard Is Double-Edged Sword For Generics
The interchangeability standard for follow-on biologics set out in Senate legislation creates a relatively smooth pathway for generic firms to seek approval of such products, but could also lead to an extended struggle to win acceptance for such products in the marketplace